NCT03356236招募中不适用
A Multicenter, Prospective Cohort Study Investigating Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation
Yue Han17 个研究点 分布在 1 个国家目标入组 828 人开始时间: 2018年4月17日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 828
- 试验地点
- 17
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
To evaluate the efficacy and safety of Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma following Local Ablation
详细描述
A multicenter, prospective cohort study investigating Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma following Local Ablation，to evaluate the efficacy and safety
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years ≤ Age ≤ 75 years, both male and female
- •Patients are diagnosed with HCC via examination of tissues according to Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma (Version 2017) by NHFPC (National Health and Family Planning Commission of the People's Republic of China) and/or HCC imaging criteria of American Association for the Study of Liver Diseases (AASLD) for the diagnosis of HCC;
- •Radiographic testing shows cancer cells have been eliminated after four weeks of Local Ablation;Complete Response (CR): Dynamic contrast-enhanced CT scans and follow-up MR images show low-density area of Hepatocellular Carcinoma and no enhancement during the arterial phase of contrast-enhanced CT; also patients with 0.5-1 cm beyond the limits of the tumor margins (considered as safe surgical margins) are eligible;
- •According to contrast-enhanced CT and MRI, with solitary tumor smaller than 5 cm in diameter; with multiple tumors (no more than 3 masses), the largest dimension is less than 3 cm;
- •Patients are eligible if Hemoglobin (Hb) count ≥90g/L, platelets count (PLT) ≥60×109/L, absolute neutrophil count (ANC) count >1.0×109/L, prothrombin activity (PTA)>50%, serum creatinine is less than 1.5 times ULN (Upper Limit of Normal) and total bilirubin (TBIL) <51.3μmol/L (3 mg/dL);
- •ECOG score of 0-1;
- •Liver function is Child - Pugh grade A or B.
- •History of TACE for treatment of HCC is less than or equal to twice -
- •The patients are volunteered for the study, sign informed consent form and cooperate with Investigator to collect data.
排除标准
- •Radiographic testing shows cancer cells have not been eliminated after four weeks of Local Ablation;
- •The occurrence of embolism occurs in large blood vessels on liver, patients with extrahepatic metastatic of HCC or liver transplantation;
- •Patients who are about to receive or already received chemotherapy or molecular targeted therapy;
- •Patients who are about to receive TACE treatment for HCC;
- •Patients without previous treatment of Huaier granules.
- •History of diabetes;
- •HCC patients with uncontrollable ascites at the beginning of enrollment of the study or are very likely to have ascites during the next four weeks at the time of enrollment; patients with hepatic encephalopathy or upper gastrointestinal bleeding;
- •Patients have basic diseases including severe cardiopulmonary insufficiency, renal insufficiency, or severe mental illness;
- •Patients with other infectious disease (excluding viral hepatitis)
- •Patients who cannot take oral medication;
- •Conditions that are considered not suitable for this study investigators.
结局指标
主要结局
Progression-free survival (PFS)
时间窗: 96 weeks
PFS was defined as the duration of time from start of treatment to time of disease progression.
次要结局
- Recurrence-Free Survival (RFS)(96 weeks)
- Overall Survival (OS)(Time from baseline to death (up to 96 weeks))
- Change From Baseline in Quality of Life (QOL)(24, 48, 72, 96 weeks)
- Time to recurrence (TTR)(Time from baseline to relapse (up to 96 weeks))
- severity of Adverse events (AE)(96 weeks)
- Incidence rate of Adverse events (AE)(96 weeks)
研究者
Yue Han
Professor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
研究点 (17)
Loading locations...
相似试验
已完成
4 期
Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical HepatectomyHepatic CarcinomaNCT01770431Qidong Gaitianli Medicines Co., Ltd1,044
招募中
不适用
Huaier Granules for Prevention of Recurrence and Metastasis of Colorectal Cancer Patients Following Radical SurgeryColorectal CancerNCT03349762Xi Shan Wang3,060
招募中
4 期
The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic CancerPancreatic Cancer ResectableNCT06368063Health Science Center of Xi'an Jiaotong University642
尚未招募
4 期
A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver CancerUnresectable Hepatocellular CarcinomaNCT05660213Fudan University750
Unknown
3 期
Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal CancerColorectal CancerNCT02785146Sixth Affiliated Hospital, Sun Yat-sen University230